|Northwest Biotherapeutics, Inc.|
4800 Montgomery Lane
United States - Map
Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. Its DCVax uses activated dendritic cells to mobilize a patients own immune system to attack their cancer. The company develops DCVax-L, which is under Phase III clinical trials for glioblastoma multiforme brain cancer and ovarian cancer, and for other cancers in situations, which the patient has their tumor surgically removed as part of standard of care; DCVax-Direct that is under Phase I/II clinical for solid tumor cancers; and DCVax-Prostate, which is under Phase III clinical trial for late stage hormone independent prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
|Ms. Linda F. Powers J.D.,
Chairperson, Chief Exec. Officer, Pres, Chief Financial Officer and Principal Accounting Officer
|Dr. Alton L. Boynton Ph.D.,
Founder, Chief Scientific Officer, Sec. and Director
|Dr. Anthony E. Maida III, MA, MBA, Ph.D.,
Chief Operating Officer
|Dr. Marnix L. Bosch Ph.D., MBA,
Chief Technical Officer
|Mr. Leslie J. Goldman ,
Sr. VP of Bus. Devel.
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|